Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended		186 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Condensed Consolidated Statements of Operations [Abstract]
Licensing revenue					$ 1,300,000
Net sales					174,830
Grant revenue					618,692
Total net revenue					2,093,522
Cost of sales					51,094
Gross margin					2,042,428
Operating expenses:
Research and development	2,050,314	918,309	4,004,180	2,791,404	76,215,147
Selling, general and administrative	1,981,869	944,950	5,379,723	3,422,843	58,336,937
Transaction-related expenses	(487,836)		1,541,087		1,871,456
Depreciation and amortization	8,498	4,879	28,735	16,526	10,926,353
In-process research and development					10,422,130
Impairment loss					5,702,130
Equity in loss of investee					178,936
Total operating expenses	3,552,845	1,868,138	10,953,725	6,230,773	163,653,089
Loss from operations	(3,552,845)	(1,868,138)	(10,953,725)	(6,230,773)	(161,610,661)
Loss on fair value of warrants					(12,239,688)
Interest income	7,343	26,258	51,212	68,006	4,733,273
Interest expense	(272)		(272)	(1,629)	(180,991)
Other income (expense)	6,448	(2,019)	14,830	(2,019)	78,205
Loss before cumulative effect of change in accounting principle	(3,539,326)	(1,843,899)	(10,887,955)	(6,166,415)	(169,219,862)
Cumulative effect of change in accounting principle					(25,821)
Net loss	(3,539,326)	(1,843,899)	(10,887,955)	(6,166,415)	(169,245,683)
Preferred stock dividends					(621,240)
Deemed dividends on preferred stock				(5,639,796)	(10,506,683)
Net loss applicable to common stock	$ (3,539,326)	$ (1,843,899)	$ (10,887,955)	$ (11,806,211)	$ (180,373,606)
Net loss per common share - basic and diluted	$ (0.13)	$ (0.13)	$ (0.43)	$ (0.94)
Weighted average shares - basic and diluted	26,465,709	14,701,216	25,170,734	12,593,971